Stock GUD KNIGHT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Delayed Toronto S.E.
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
5.79 CAD -1.19% Intraday chart for Knight Therapeutics Inc. -1.36% +11.56%
Mar. 22 Knight Therapeutics Price Target Raised to $7 at RBC MT
Mar. 21 Knight Therapeutics Reports Fourth Quarter Results MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GL
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
GL
Knight Therapeutics Price Target Raised to $7 at RBC
MT
Knight Therapeutics Reports Fourth Quarter Results
MT
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024
CI
Transcript : Knight Therapeutics Inc., Q4 2023 Earnings Call, Mar 21, 2024
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Knight Therapeutics Inc. Announces Impairment Charges for the Fourth Quarter of 2023
CI
Knight Therapeutics Reports Fourth Quarter and Year-End 2023 Results
GL
Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : Investors -2-
DJ
North American Morning Briefing : Investors Continue to Cheer Reassuring Fed
DJ
Notice of Knight Therapeutics' Fourth Quarter and Year End 2023 Results Conference Call
GL
Knight Therapeutics Announces Launch of Minjuvi in Brazil
MT
Knight Therapeutics Brief: Announcing Launch of Minjuvi in Brazil
MT
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
GL
Knight Therapeutics Announces Launch of Minjuvi® in Brazil
AQ
Knight Therapeutics Inc. Celebrates its First Decade of Success
GL
Knight Therapeutics Brief: Announcing Regulatory Submission Of Fostamatinib In Brazil
MT
Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GUD Stock
  4. News Knight Therapeutics Inc.